Table 1.
Classification of Patients Using the Model’s Rules and ODX/TAILORx Risk Groups
| Data Set | ODX Low Risk | ODX Intermediate | ODX High Risk | Total | ||
|---|---|---|---|---|---|---|
| TX NC | TAILORx Intermediate | TX Chemo | ||||
| RS <11 | 11–17 | 18–25 | 26–30 | RS >30 | ||
| AAMC Dev (Development) | ||||||
| HG/LER | 0 | 2 (5%) | 4 (11%) | 6 (16%) | 25 (68%) | 37 |
| Indeterminate | 19 (17%) | 41 (37%) | 35 (32%) | 8 (7%) | 8 (7%) | 111 |
| LG+PR | 27 (37%) | 33 (45%) | 13 (18%) | 0 | 0 | 73 |
| Total | 46 (21%) | 76 (34%) | 52 (24%) | 14 (6%) | 33 (15%) | 221 |
| AAMC Superset (Consults Included) | ||||||
| HG/LER | 1 (2%) | 5 (10%) | 7 (15%) | 8 (17%) | 27 (56%) | 48 |
| Indeterminate | 37 (19%) | 72 (38%) | 54 (28%) | 14 (7%) | 13 (7%) | 190 |
| LG+PR | 31 (34%) | 42 (46%) | 18 (20%) | 0 | 0 | 91 |
| Total | 69 (21%) | 119 (36%) | 79 (24%) | 22 (7%) | 40 (12%) | 329 |
| JHH MAIN (Main Hospital Only) | ||||||
| HG/LER | 1 (2.6%) | 8 (21%) | 11 (29%) | 6 (16%) | 12 (32%) | 38 |
| Indeterminate | 33 (19%) | 63 (36%) | 59 (34%) | 12 (7%) | 8 (5%) | 175 |
| LG+PR | 7 (28%) | 12 (48%) | 6 (24%) | 0 | 0 | 25 |
| Total | 41 (17%) | 83 (35%) | 76 (32%) | 18 (8%) | 20 (8%) | 238 |
| JHH Superset (Consults Included) | ||||||
| HG/LER | 1 (2%) | 10 (20%) | 13 (27%) | 7 (14%) | 18 (37%) | 49 |
| Indeterminate | 39 (17%) | 88 (38%) | 78 (34%) | 16 (7%) | 11 (5%) | 232 |
| LG+PR | 11 (29%) | 17 (45%) | 9 (24%) | 0 | 1 (2.6%) | 38 |
| Total | 51 (16%) | 115 (36%) | 100 (31%) | 23 (7.2%) | 30 (9%) | 319 |
Abbreviations: AAMC = Anne Arundel Medical Center; Chemo = chemotherapy; HG/LER = high grade or low estrogen receptor; JHH = Johns Hopkins Hospital; LG + PR = low grade and progesterone receptor-positive; NC = no chemotherapy; ODX = Oncotype DX (Genomic Health, Redwood City, CA); TAILORx = Trial Assigning Individualized Options for Treatment (Rx); TX = treatment.